

PRECEPTORSHIP PROGRAMME

Non-Small-Cell Lung Cancer

**ESMO
PRECEPTORSHIP**

**SINGAPORE
10-11 JANUARY 2023**

Standards of care, evolving paradigm
and future perspectives

Co-Chairs

Pasi A. Jänne, United States
Tony S. K. Mok, Hong Kong
Solange Peters, Switzerland

ESMO PRECEPTORSHIP PROGRAMME NON-SMALL-CELL LUNG CANCER

Standards of care, evolving paradigm and future perspectives

Singapore
10-11 January 2023

CO-CHAIRS Pasi A. Jänne, United States
Tony S. K. Mok, Hong Kong
Solange Peters, Switzerland

SPEAKERS Maximilian Diehn, United States
Rafal Dziadziuszko, Poland
Keith M. Kerr, United Kingdom
Se-Hoon Lee, Republic of Korea
Natasha Leighl, Canada
Tetsuya Mitsudomi, Japan
Antonio Passaro, Italy
David Planchard, France
Daniel S. W. Tan, Singapore
Junko Tanizaki, Japan
Pan-Chyr Yang, Taiwan

LEARNING OBJECTIVES

- To learn about best clinical practice in the management of Non-Small-Cell Lung Cancer (NSCLC) in the adjuvant, locally advanced and metastatic setting
- To understand the importance of pathology, histo-prognostic and molecular factors and liquid biopsies in the management of NSCLC
- To learn about the management of patients after progression, side effects of treatments and the use of targeted agents in NSCLC and obtain some highlights of ongoing clinical research

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Tuesday, 10 January 2023

09:00-09:10 10'	Opening and welcome	
10'	Introduction and objectives	Tony S. K. Mok, HK Solange Peters, CH
09:10-10:05 55'	SESSION 1 Screening, diagnosis and staging	Chair: Solange Peters, CH
20'	Early detection of lung cancer: Biology, screening and cost-effectiveness	Pan-Chyr Yang, TW
20'	The role of pathology and genetic/molecular analyses	Keith M. Kerr, UK
15'	Discussion	Faculty
10:05-10:35	Coffee break	
10:35-11:30 55'	SESSION 2 Adjuvant therapy	Chair: Tony S. K. Mok, HK
20'	Adjuvant/Neo-adjuvant chemotherapy and radiotherapy strategies for resected NSCLC	Natasha Leighl, CA
20'	Adjuvant and neo-adjuvant targeted and immunotherapeutic agents: Clinical evidence and clinical research	Daniel S. W. Tan, SG
15'	Discussion	Faculty
11:30-12:10 40'	SESSION 3 Multi-disciplinary lung tumour board – Part. I	Chair: Pasi A. Jänne, US
40'	Management of stage III - Case presentation <ul style="list-style-type: none"> - Surgeon's point of view - Radiotherapist's point of view - Medical oncologist's point of view - Discussion 	Tetsuya Mitsudomi, JP Rafal Dziadziuszko, PL Antonio Passaro, IT
12:10-12:50 40'	SESSION 4 Multi-disciplinary lung tumour board – Part. II	Chair: Solange Peters, CH
40'	Management of oligometastatic disease - Case presentation <ul style="list-style-type: none"> - Surgeon's point of view - Radiotherapist's point of view - Medical oncologist's point of view - Discussion 	Tetsuya Mitsudomi, JP Rafal Dziadziuszko, PL Tony S. K. Mok, HK
12:50-13:50	Lunch	
13:50-14:50 60'	SESSION 5 Audience cases	Chair: Tony S. K. Mok, HK
60'	Participants clinical case discussion (6x10')	Faculty
14:50-15:20	Coffee break	

15:20-16:15 55'	SESSION 6 Systemic therapy for advanced NSCLC	Chair: Tony S. K. Mok, HK
20'	Immune Checkpoint Inhibitors as a consolidation in stage III NSCLC	Se-Hoon Lee, KR
20'	Immune Checkpoint Inhibitors across lines of metastatic NSCLC	Solange Peters, CH
15'	Discussion	Faculty
17:00	Networking cocktail reception	

Wednesday, 11 January 2023

08:30-10:25 115'	SESSION 7 Targeted therapies	Chair: Solange Peters, CH
20'	Systemic therapy for non-oncogene addicted NSCLC	Natasha Leighl, CA
20'	New treatment options for EGFR-mutated NSCLC	Tony S. K. Mok, HK
20'	New treatment options for ALK-ROS1 rearranged NSCLC	David Planchard, FR
20'	KRAS mutant NSCLC	Pasi A. Jänne, US
20'	RET/TRK/BRAF/MET	Antonio Passaro, IT
15'	Discussion	Faculty
10:25-10:55	Coffee break	
10:55-11:25 30'	SESSION 8 Audience cases	Chairs: Tony S. K. Mok, HK
30'	Participants clinical case discussion (3x10')	Faculty
11:25-13:00 95'	SESSION 9 Other thoracic tumours and molecular testing	Chair: Pasi A. Jänne, US
20'	Optimal platform and sequence for biomarker testing in advanced NSCLC: IHC, PCR, NGS and more	Keith M. Kerr, UK
20'	Liquid biopsy applications in the early detection and management of NSCLC patients	Maximilian Diehn, US
20'	Immunotherapy for SCLC	Junko Tanizaki, JP
20'	Immunotherapy for mesothelioma	Rafal Dziadziuszko, PL
15'	Discussion	Faculty
13:00-13:10 10'	Conclusion and take home messages	Pasi A. Jänne, US Tony S. K. Mok, HK Solange Peters, CH
13:10-14:10	Lunch	

Note: Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion